RNA Therapeutics
Developers of RNAi, antisense and mRNA therapeutics (excluding vaccines).
Leadership as of 2026-10-27: Lagging. Relative to SPY: 5 sessions −0.6pp, 21 sessions −4.2pp, 63 sessions −28.8pp. Participation 40%; 5 of 5 members eligible.
- 21-session excess -4.2pp
- 63-session excess -31.7pp (robust)
Economic family: Biotechnology
Member companies
Related themes
- Large-Cap Biopharma: Leading — 21-session vs SPY +6.1pp, participation 75%
- Neuro / CNS: Neutral — 21-session vs SPY −0.2pp, participation 43%
- Molecular Diagnostics: Weakening — 21-session vs SPY +15.9pp, participation 80%
- Immunology & Inflammation: Lagging — 21-session vs SPY −3.6pp, participation 29%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- Oncology: Lagging — 21-session vs SPY −8.2pp, participation 32%
- Gene Therapy: Lagging — 21-session vs SPY −16.6pp, participation 0%
- Targeted Protein Degradation: Tracked (too few stocks for a leadership state) — 21-session vs SPY +2.4pp, participation 67%